Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

NCT07708714 is registered in ClinicalTrials.gov with Children's Hospital Medical Center, Cincinnati as lead sponsor.

NCT NCT07708714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07708714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 13, 2026
Completion date
November 30, 2032
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell anemia in children, sickle cell disease